Tianzuo Yuan

Mr. Tianzuo Yuan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2025 in Biomimetics
Verified
Journal Article
Open access
PDF file
TYTianzuo Yuan
Tianzuo Yuan
HZHuanzun Zhang
Huanzun Zhang
JJJie Jin
Jie Jin
ZCZhebo Chen
Zhebo Chen
SCShanshan Cai
Shanshan Cai
Superb Fairy-wren Optimization Algorithm (SFOA) is an animal-based meta-heuristic algorithm derived from Fairy-wren’s behavior of growing, feeding, and avoiding natural enemies. The SFOA has some shortcomings when facing complex environments. Its switching mechanism is not enough to adapt to complex optimization problems, and it faces a weakening of population diversity in the late stage of optimization, leading to a higher possibility of falling into local optima. In addition, its global search ability needs to be improved. To address the above deficiencies, this paper proposes an Adaptive Superb Fairy-wren Optimization Algorithm (ASFOA). To assess the ability of the proposed ASFOA, three groups of experiments are conducted in this paper. Firstly, the effectiveness of the proposed improved strategies is checked on the CEC2018 test set. Second, the ASFOA is compared with eight classical/highly cited/newly proposed metaheuristics on the CEC2018 test set, in which the ASFOA performed the best overall, with average rankings of 1.621, 1.138, 1.483, and 1.966 in the four-dimensional cases, respectively. Then the convergence and robustness of ASFOA is verified on the CEC2022 test set. The experimental results indicate that the proposed ASFOA is a competitive metaheuristic algorithm variant with excellent performance in terms of convergence and distribution of solutions. In addition, we further validate the ability of ASFOA to solve real optimization problems. The average ranking of the proposed ASFOA on 10 engineering constrained optimization problems is 1.500. In summary, ASFOA is a promising variant of metaheuristic algorithms.



19 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TYTianzuo Yuan
Tianzuo Yuan
Background. Oncology trial pre-screening is a high-risk clinical decision support task in which complex eligibility criteria must be matched against heterogeneous patient information. Unsafe false inclusion—incorrectly labelling an ineligible patient as eligible—may be more consequential than general misclassification, yet many AI evaluations emphasize overall accuracy without explicitly assessing this error type or the role of uncertainty-aware abstention.Objective. To evaluate safety-aware AI approaches for oncology trial pre-screening by comparing rule-based, single-agent large language model (LLM), and multi-agent systems on a fully manually reviewed non-small cell lung cancer (NSCLC) cohort, with explicit emphasis on false inclusion reduction and uncertainty-aware triage.Methods. We constructed an NSCLC-focused trial pre-screening dataset using interventional trial eligibility text and structured synthetic patient summaries spanning clinically relevant variation in stage, biomarker status, prior therapy, performance status, and exclusion-relevant factors. A total of 120 patient–trial pairs were fully manually reviewed and divided into a development set (n=30) and a held-out test set (n=90). Five system configurations were evaluated: a rule-based baseline, a rule-based system with conservative Safety Agent gating, a single-agent LLM baseline (GPT-4o-mini), and two lightweight multi-agent configurations (M1, M2). The primary safety metric was false inclusion; secondary metrics were accuracy and uncertain rate. External validation used 120 pairs derived from TCGA-LUAD clinical data.Results. Safety Agent gating reduced false inclusion from 11.63% to 1.16% on the combined 120-pair cohort and from 12.12% to 1.52% on the held-out test set (McNemar p=0.002), with a corresponding increase in uncertain rate. The single-agent LLM achieved the strongest overall performance: accuracy 0.74, no observed false inclusion, uncertain rate 7.5%. Multi-agent systems reduced false inclusion versus the rule-based baseline but were more conservative than the single-agent LLM. External validation confirmed no false inclusion under incomplete evidence for both safety-gated and LLM-based systems.Conclusions. Safety-aware gating substantially reduced false inclusion in rule-based pre-screening; the single-agent LLM provided the strongest observed performance baseline. These findings support explicit false inclusion monitoring, uncertainty-aware abstention, and multi-dimensional evaluation as key requirements for AI-assisted oncology trial pre-screening, pending validation in larger real-world cohorts.

7 July 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YJYanjun Jin
Yanjun Jin
TYTianzuo Yuan
Tianzuo Yuan
ZCZhiyuan Chen
Zhiyuan Chen
Background: Artificial intelligence (AI) has emerged as a promising tool for prostate cancer (PCa) risk stratification and outcome prediction. However, current studies often lack multicenter external validation, have limited sample sizes, present significant intermodel variability, and face overfitting concerns. Objective: This study aimed to comprehensively evaluate the diagnostic performance of magnetic resonance imaging (MRI)–based AI models in predicting biochemical recurrence (BCR) of PCa. Methods: Systematic searches were conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases up to January 13, 2026. Studies were included that involved participants diagnosed with PCa, used MRI-based AI for predicting BCR, and had clearly defined reference standards. The quality of the included studies was assessed using the PROBAST+AI tool. A bivariate random effects model was used to pool sensitivity, specificity, and area under the curve (AUC) statistics. Results: A total of 28 studies were included, with 2623 patients in internal validation and 1134 patients in external validation. Diagnostic contingency tables were reconstructed from published performance metrics for most studies, while others were extracted from receiver operating characteristic curves due to the lack of direct reporting. In the internal validation set, pooled sensitivity was 0.80 (95% CI 0.73‐0.86; prediction interval [PI] 0.48‐0.99), specificity was 0.83 (95% CI 0.77‐0.89; PI 0.49‐1.00), and AUC was 0.86 (95% CI 0.83‐0.89; PI 0.74‐0.99). In the external validation set, pooled sensitivity was 0.82 (95% CI 0.72‐0.91; PI 0.54‐0.99), specificity was 0.83 (95% CI 0.71‐0.92; PI 0.49‐1.00), and AUC was 0.84 (95% CI 0.79‐0.90; PI 0.70‐0.98). No statistically significant differences were observed between internal and external validation in sensitivity ( P =.73), specificity ( P >.99), AUC ( P =.53), or diagnostic odds ratio ( P =.98). Medical Net and Extreme Gradient Boosting achieved the highest sensitivity and AUC, whereas multiple kernel learning and support vector machine had the highest specificity. Subgroup and meta-regression analyses suggested that AI method, model type, timing of MRI acquisition, and treatment modality may contribute to heterogeneity. Conclusions: This meta-analysis innovatively realizes the quantitative direct comparison of MRI-based AI model performance between internal and external validation cohorts for PCa BCR prediction. It comprehensively evaluates AI performance across diverse PCa treatment modalities and integrates machine learning and deep learning approaches. For the field, it identifies key sources of performance heterogeneity (eg, MRI acquisition timing and treatment modality) and quantifies the sensitivity-specificity trade-off in integrated radiomic-clinical models, advancing the systematic understanding of MRI-based AI for BCR prediction. In real-world practice, it provides actionable guidance to prioritize pretreatment MRI for AI model development and clinical BCR assessment and underscores the urgent need for standardized imaging protocols and prospective multicenter studies, laying a foundation for the safe clinical translation of these AI tools as adjunctive decision support instruments.